N/A
Manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
53,036 FDA adverse event reports analyzed
Last updated: 2026-04-14
DESVENLAFAXINE SUCCINATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. The most commonly reported adverse reactions for DESVENLAFAXINE SUCCINATE include DRUG INEFFECTIVE, NAUSEA, HEADACHE, DIZZINESS, ANXIETY. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for DESVENLAFAXINE SUCCINATE.
Out of 26,263 classified reports for DESVENLAFAXINE SUCCINATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 53,036 FDA FAERS reports that mention DESVENLAFAXINE SUCCINATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, NAUSEA, HEADACHE, DIZZINESS, ANXIETY, FATIGUE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. in connection with DESVENLAFAXINE SUCCINATE. Always verify the specific product and NDC with your pharmacist.